Nav: Home

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis

May 06, 2019

Men treated with medications for symptoms of benign prostatic hyperplasia (BPH) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis, report University of California San Diego School of Medicine researchers.

Men who took drugs that inhibit the enzyme 5α-reductase, known as 5-ARIs, were diagnosed with prostate cancer 3.6 years after the first signs of elevated levels of a protein called prostate-specific antigen (PSA) compared to 1.4 years for men who did not use 5-ARI. The findings are published in the May 6, 2019 online issue of JAMA Internal Medicine.

"Our study demonstrates how important it is to raise awareness among medical care teams and patients that 5-ARI inhibitors can cause PSA-suppression," said Brent S. Rose, MD, assistant professor in the Department of Radiation Medicine and Applied Sciences at UC San Diego School of Medicine and senior author on the paper. "In addition, there is a need to create clear guidelines for early prostate cancer detection to facilitate optimal care for men prescribed 5-ARIs."

Previous studies have shown that treatment with 5-ARIs can result in an approximately 50 percent reduction in the levels of PSA, a protein produced by the prostate gland. Because prostate cancer can cause an increase in PSA levels, the PSA test is used as a screening tool for this cancer type.

Men are prescribed 5-ARI to reduce the effects of BPH, a non-cancerous condition in which the enlarged prostate squeezes or blocks the urethra. This condition affects more than 50 percent of men above the age of 50. It can lead to urinary symptoms, such as difficulty starting or stopping urination and the constant feeling of needing to urinate.

Data from the population-based cohort study of 80,875 men with a PSA-known diagnosis between 2001 and 2015 showed that 29 percent of 5-ARI users had a biopsy performed within two years of first elevated adjusted PSA compared to 59 percent of nonusers.

Twenty-five percent of 5-ARI users were diagnosed with high-grade cancers --malignancies that grow and spread quickly and have a worse prognosis -- while 17 percent of nonusers presented with high-grade cancers. In addition, 7 percent of users had metastatic disease compared to 3 percent of nonusers.

"Using PSA screening continues to be an effective tool for prostate cancer detection among men using 5-ARI, so long as PSA levels are adjusted for PSA suppression that occurs while taking these drugs," said Reith R. Sarkar, clinical research associate in the Department of Radiation Medicine and Applied Sciences and first author on the paper. "Our data suggest that PSA suppression in this population was not routinely accounted for during screening for pancreatic cancer and that this led to delays in diagnosis, which may have resulted in advanced disease and worsened clinical outcomes."
-end-
Co-authors include: J. Kellog Parsons, Alex K. Bryant, Stephen T. Ryan, Andrew K. Kader, Rana R. McKay, John P. Einck, Arno J. Mundt, Christopher J. Kane, and James D. Murphy, all at UC San Diego; Anthony V. D'Amico and Paul L. Nguyen, Harvard Medical School; and Benjamin J. Hulley, UC San Diego and Veterans Affairs San Diego Healthcare System.

University of California - San Diego

Related Prostate Cancer Articles:

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
Patient prostate tissue used to create unique model of prostate cancer biology
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Moffitt Cancer Center awarded $3.2 million grant to study bone metastasis in prostate cancer
Moffitt researchers David Basanta, Ph.D., and Conor Lynch, Ph.D., have been awarded a U01 grant to investigate prostate cancer metastasis.
Prostate cancer discovery may make it easier to kill cancer cells
A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy.
New test for prostate cancer significantly improves prostate cancer screening
A study from Karolinska Institutet in Sweden shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
More Prostate Cancer News and Prostate Cancer Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.